Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Lonza Unit Launches Colorista Capsule to Cut Down on Development Time

By Lonza Group Ltd | September 4, 2018

(Credit: Lonza Group Ltd.)

Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is launching Capsugel Colorista, a high-quality capsule based on an “all-colorants” formulation. The new capsule further expands the Lonza Capsugel R&D offering. 

Colorista capsules contain a broad selection of colorants suitable for use in major markets, allowing pharmaceutical customers to have access to a wide array of colors, and are available in both Vcaps Plus (HPMC) and Coni-Snap gelatin.

“A common issue faced by drug product developers is that the color composition choice for the commercial drug product is often made after initial stability studies,” said Emmanuelle Saugues, Color Lab EMEA supervisor for Lonza. “If new colors are introduced, it may require additional studies, which can result in costly delays. To address this problem, we have developed Colorista capsules at the Capsugel Color Lab.”  

Colorista capsules offer more than 150 color options in Coni-Snap gelatin capsules and more than 50 color options in Vcaps Plus capsules and are available in different sizes to enable the encapsulation of a wide range of doses and formulations.

“Colorista capsules meet the demand of our pharmaceutical customers who look for solutions that cut down on development time while giving them flexibility to progress with technical development before the final commercial color decision is taken,” Niki Kolokotronis, sales director Americas for Capsule Delivery Solutions, said. 

(Source: Lonza Group Ltd.)

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards